|Serine Protease Inhibitor WX-671 (Code C73985)|
|Terms & Properties|
Preferred Name: Serine Protease Inhibitor WX-671
Definition: An orally bioavailable, 3-amidinophenylalanine-derived, second generation serine protease inhibitor prodrug targeting the human urokinase plasminogen activator (uPA) system with potential antineoplastic and antimetastatic activities. After oral administration, serine protease inhibitor WX-671 is converted to the active N alpha-(2,4,6-triisopropylphenylsulfonyl)-3-amidino-(L)-phenylalanine-4-ethoxycarbonylpiperazide (WX-UK1), which inhibits several serine proteases, particularly uPA; inhibition of uPA may result in the inhibition of tumor growth and metastasis. uPA is a serine protease involved in degradation of the extracellular matrix and tumor cell migration and proliferation.
NCI-GLOSS Definition: A substance being studied in the treatment of several types of cancer. It blocks the action of certain enzymes, and it may help keep cancer cells from growing and spreading. It is a type of serine protease inhibitor.
Display Name: Serine Protease Inhibitor WX-671
Label: Serine Protease Inhibitor WX-671
NCI Metathesaurus Link: C2348191 (see NCI Metathesaurus info)
Synonyms & Abbreviations: (see Synonym Details)
|Serine Protease Inhibitor WX-671|
External Source Codes:
|PDQ Closed Trial Search ID||557106|
|PDQ Open Trial Search ID||557106 (check for NCI PDQ open clinical trial info)|
|Name||Value (qualifiers indented underneath)|
Additional Concept Data:
|Defined Fully by Roles: No|